<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548652</url>
  </required_header>
  <id_info>
    <org_study_id>00469</org_study_id>
    <nct_id>NCT00548652</nct_id>
  </id_info>
  <brief_title>Role of Apathy in the Effectiveness of Weight Loss Interventions</brief_title>
  <official_title>Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Nebraska Western Iowa Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Nebraska Western Iowa Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treating apathy with methylphenidate or
      medical Crisis counselling will increase adherence to weight loss programs thereby increasing
      their effectiveness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients

      Objective: Obesity is a major public health problem. Apathy is a common behavioral problem
      characterized by loss of initiative, poor motivation and persistence. Presence of apathy
      impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's
      ability to seek new interactions, life styles and new treatment options for obesity. Lack of
      motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack
      of persistence impairs the compliance with these regimens. Thus, apathy influences all stages
      of self-care. We hypothesize that the treatment of apathy will result in better adherence to
      weight loss interventions in obese veterans enrolled in the MOVE program.

      Research Design: A prospective open label randomized study. Group 1 will have patients with
      obesity as defined as BMI&gt;30, and apathy defined as AES score of &gt; 40. This group will be
      treated with standard nutrition counseling. Group 2 will have patients with obesity and
      apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program
      is a national VA weight loss program). Group 3 will be treated with methylphenidate along
      with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling
      along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and
      the medical crisis counseling along with the MOVE enhancement program.

      Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All
      patients will be in the study for duration of six months. All patients in the methylphenidate
      arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks.
      Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton
      Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly
      from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every
      week for nine sessions and then every other week till the end of the study

      Clinical Relationships/Significance: The prevalence of obesity in the general population is
      over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since
      obesity predisposes to several co-morbid conditions such as hypertension, diabetes and
      cardiovascular disease, it is important to develop interventions that are effective in
      inducing weight loss. Since apathy plays a large role in the self care behaviours that lead
      to obesity, treating apathy may improve adherence to weight loss programs
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apathy Evaluation Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>6 months</time_frame>
    <description>value at 6 months minus value at baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Obesity</condition>
  <condition>Apathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard nutrition counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOVE -weight loss intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOVE plus medical crisis counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOVE plus methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOVE plus methyphenidate plus medical crisis counselling</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MOVE</intervention_name>
    <description>is a VA based multidesciplinary weight loss intervention</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>medical crisis councelling</intervention_name>
    <description>group counselling sessions</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MOVE</intervention_name>
    <description>is a VA based multidesciplinary weight loss intervention</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyphenidate</intervention_name>
    <description>methyphenidate will be used to treat apathy dose 10mg bid</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MOVE</intervention_name>
    <description>is a VA based multidesciplinary weight loss intervention</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyphenidate</intervention_name>
    <description>methyphenidate will be used to treat apathy dose 10mg bid</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>medical crisis councelling</intervention_name>
    <description>group counselling sessions</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MOVE</intervention_name>
    <description>is a VA based multidesciplinary weight loss intervention</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;30

          -  Apathy score &gt;40

        Exclusion Criteria:

          -  History of cancer, except basal cell

          -  Cardiovascular event in last 6 months

          -  Renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrus DeSouza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Omaha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <results_first_submitted>June 19, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Nebraska Western Iowa Health Care System</investigator_affiliation>
    <investigator_full_name>Prasad R. Padala</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>apathy</keyword>
  <keyword>obesity</keyword>
  <keyword>methylphenidate</keyword>
  <keyword>MOVE</keyword>
  <keyword>medical crisis counselling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>standard nutrition counselling</description>
        </group>
        <group group_id="P2">
          <title>VA MOVE</title>
          <description>MOVE -weight loss intervention
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
        <group group_id="P3">
          <title>Intervention</title>
          <description>MOVE plus methylphenidate
methyphenidate: methyphenidate will be used to treat apathy dose 10mg bid
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>standard nutrition counselling</description>
        </group>
        <group group_id="B2">
          <title>VA MOVE</title>
          <description>MOVE -weight loss intervention
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
        <group group_id="B3">
          <title>Intervention</title>
          <description>MOVE plus methylphenidate
methyphenidate: methyphenidate will be used to treat apathy dose 10mg bid
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="14.3"/>
                    <measurement group_id="B2" value="55.2" spread="10.1"/>
                    <measurement group_id="B3" value="52.5" spread="10.4"/>
                    <measurement group_id="B4" value="52.34" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.06" spread="5.91"/>
                    <measurement group_id="B2" value="38.78" spread="5.6"/>
                    <measurement group_id="B3" value="37.58" spread="5.69"/>
                    <measurement group_id="B4" value="37.21" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apathy Evaluation Scale</title>
          <description>Score range 18-72 Higher score indicates more apathy</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.89" spread="8.2"/>
                    <measurement group_id="B2" value="42.12" spread="7.93"/>
                    <measurement group_id="B3" value="42.96" spread="8.94"/>
                    <measurement group_id="B4" value="42.06" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apathy Evaluation Scale</title>
        <description>Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>standard nutrition counselling</description>
          </group>
          <group group_id="O2">
            <title>VA MOVE</title>
            <description>MOVE -weight loss intervention
MOVE: is a VA based multidesciplinary weight loss intervention</description>
          </group>
          <group group_id="O3">
            <title>Intervention</title>
            <description>MOVE plus methylphenidate
methyphenidate: methyphenidate will be used to treat apathy dose 10mg bid
MOVE: is a VA based multidesciplinary weight loss intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Apathy Evaluation Scale</title>
          <description>Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.69" spread="6.77"/>
                    <measurement group_id="O2" value="-6.4" spread="7.35"/>
                    <measurement group_id="O3" value="-6.15" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>value at 6 months minus value at baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>standard nutrition counselling</description>
          </group>
          <group group_id="O2">
            <title>VA MOVE</title>
            <description>MOVE -weight loss intervention
MOVE: is a VA based multidesciplinary weight loss intervention</description>
          </group>
          <group group_id="O3">
            <title>Intervention</title>
            <description>MOVE plus methylphenidate
methyphenidate: methyphenidate will be used to treat apathy dose 10mg bid
MOVE: is a VA based multidesciplinary weight loss intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>value at 6 months minus value at baseline</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.73"/>
                    <measurement group_id="O2" value="-0.61" spread="7.14"/>
                    <measurement group_id="O3" value="-4.61" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>standard nutrition counselling</description>
        </group>
        <group group_id="E2">
          <title>VA MOVE</title>
          <description>MOVE -weight loss intervention
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
        <group group_id="E3">
          <title>Intervention</title>
          <description>MOVE plus methylphenidate
methyphenidate: methyphenidate will be used to treat apathy dose 10mg bid
MOVE: is a VA based multidesciplinary weight loss intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cyrus Desouza</name_or_title>
      <organization>VANebraska</organization>
      <phone>4023468800 ext 5506</phone>
      <email>cyrus.desouza@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

